首页> 外文期刊>National Journal of Medical Research >Retrospective study of Hormone Receptor status in Breast Cancer Patients in Central India
【24h】

Retrospective study of Hormone Receptor status in Breast Cancer Patients in Central India

机译:印度中部乳腺癌患者激素受体状态的回顾性研究

获取原文
       

摘要

Abstract Background Breast cancer, in India, is the second most cancer in females. Hormone receptor status with ER/PR is now routinely done in patients with invasive carcinoma. We have done single institutional retrospective study with the aim to evaluate the ER, PR receptors in invasive breast carcinomas patients in central India. Materials and Methods: This retrospective study was done on breast carcinoma patients coming to Sri Aurobindo institute of medical sciences, Indore. Data were collective from medical records of breast carcinoma patients from January 2013 to may 2016.Total 149 cases of histopathologically diagnosed carcinoma breast were registered out of which 144 patients with different histology?s were evaluated taking into account various parameters like age, sex ,histology, stage, background ,menstrual status, hormone receptor status. Results: Out of 149 patients registered 144 patient?s data were available for hormone receptors status. The age range was 25-85 years with a median of 53 years. Out of 144 patients, 78 percent were of invasive ductal carcinoma and 16 percent were of invasive lobular carcinoma. Our data showed total 39 percent patients were positive with both ER and PR(ER+PR+) and 44% patients were negative for both ER and PR(ER-PR-). Overall ER+ was 54% and PR+ was 44%. Out of total 80 hormone positive patients 28 % were only ER positive and 2.5% were only PR positive. Conclusion: Hormone receptor positive status is low compared to western population and comparable with other Indian population studies.
机译:抽象背景在印度,乳腺癌是女性第二大癌症。 ER / PR的激素受体状态现在通常在浸润性癌患者中进行。我们已经进行了一次机构回顾性研究,旨在评估印度中部浸润性乳腺癌患者的ER,PR受体。资料和方法:这项回顾性研究是针对来自印多尔Sri Aurobindo医学研究所的乳腺癌患者进行的。数据收集自2013年1月至2016年5月的乳腺癌患者的病历。总共登记了149例经组织病理学诊断为乳腺癌的乳腺癌患者,其中144例根据年龄,性别,组织学等各种参数进行了评估,阶段,背景,月经状态,激素受体状态。结果:在149例患者中,有144例患者的激素受体状态数据可用。年龄范围为25-85岁,中位数为53岁。在144例患者中,有78%为浸润性导管癌,而16%为浸润性小叶癌。我们的数据显示,总共39%的患者ER和PR(ER + PR +)均为阳性,而44%的患者ER和PR(ER-PR-)均为阴性。总体ER +为54%,PR +为44%。在80名激素阳性患者中,只有28%的患者为ER阳性,而2.5%的患者仅为PR阳性。结论:与西方人群相比,激素受体阳性状态较低,与其他印度人群研究相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号